NIKKEI 225
38,460.08 +907.92 (+2.42%) HANG SENG
17,201.27 +372.34 (+2.21%) CRUDE OIL
82.91 -0.45 (-0.54%) GOLD FUTURES
2,332.10 -10.00 (-0.43%) DOW
38,460.92 -42.77 (-0.11%) Bitcoin GBP
51,378.13 -1,834.47 (-3.45%)
UroGen Pharma Ltd. (0XOD.L)
| Previous close | 13.50 |
| Open | 14.58 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 14.58 - 14.58 |
| 52-week range | 7.83 - 24.01 |
| Volume | |
| Avg. volume | 457 |
| Market cap | 2.041M |
| Beta (5Y monthly) | 1.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
PRINCETON, N.J., April 17, 2024--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that new data on investigational drug UGN-102 (mitomycin) and JELMYTO and will be presented at the American Urological Association (AUA) 2024 Annual Meeting being held in San Antonio, Texas from May 3 – 6.
- Business Wire
UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
PRINCETON, N.J., April 15, 2024--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced the U.S. Food and Drug Administration (FDA) accepted the Company’s Investigational New Drug (IND) application for UGN-103, a next-generation novel mitomycin-based formulation for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
- Business Wire
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals
PRINCETON, N.J., April 03, 2024--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it has filed a lawsuit in the U.S. District Court for the District of Delaware against Teva Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., and Teva Pharmaceutical Industries, Ltd., alleging infringement of U.S. Patent Numbers 9,040,074 ("the ’074 patent") and 9,950,069 ("the ’069
